Universitätsklinikum Essen

Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies (2020) Kalwak K, Mielcarek M, Patrick K, Styczynski J, Bader P, Corbacioglu S, Burkhardt B, et al. Journal article Twelve-month outcome in juvenile proliferative lupus nephritis: results of the German registry study (2020) Suhlrie A, Hennies I, Gellermann J, Buescher A, Hoyer P, Waldegger S, Wygoda S, et al. Journal article Image-based molecular phenotyping of pancreatic ductal adenocarcinoma (2020) Kaissis GA, Ziegelmayer S, Lohoefer FK, Harder FN, Jungmann F, Sasse D, Muckenhuber A, et al. Journal article Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology (2020) David P, Drabczyk-Pluta M, Pastille E, Knuschke T, Werner T, Honke N, Megger DA, et al. Journal article Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients (2020) Amaral T, Kiecker F, Schaefer S, Stege H, Kaehler K, Terheyden P, Gesierich A, et al. Journal article Malformationen des Zentralnervensystems - Seltene Ursachen eines organischen Wachstumshormonmangels bei Kindern (2020) Dörr HG, Bettendorf M, Binder G, Hauffa B, Mohnike K, Mueller HL, Reinehr T, et al. Journal article Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial (2020) Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, et al. Journal article A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast) (2020) Ahrens M, Escudier B, Boleti E, Grimm MO, Goupir MG, Barthelemy P, Gravis G, et al. Conference contribution Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab (CD-Bev) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in Patients with Recurrent Ovarian Cancer: a Prospective Randomized Phase iii Engot/GCiG-Intergroup Study (Ago Study Group, Ago-AUSTRiA, ANZGOG,GiNECO, SGCTG) (2020) Hanker L, Harter P, Sehoul L, Rau J, Canzler U, Schmalfeldt B, Thiel F, et al. Conference contribution Phase III PAOLA-1/ENGOT-OV25 Trial: Olaparib Plus Bevacizumab (BEV) As Maintenance Therapy in Patients (PTS) with Newly Diagnosed, Advanced Ovarian Cancer (OC) Treated with Platinum-Based Chemotherapy (PCH) Plus Bev (2020) De Gregorio N, Harter P, Sehouli L, Canzler U, Marme F, Buderath P, Lueck HJ, et al. Conference contribution